Donate Today Log In

Precision Rheumatology Hero

Autoimmunity · Precision Medicine

Redefining Autoimmune Care Through
Precision Rheumatology

Autoantibodies · Synovial Biology · Immunophenotyping · Flare Prediction · Treat-to-Target · Biologic Therapy

Joint

Preservation

Multi

Biomarker Panels

100%

Precision Dosing

Remission

Focused Goals

Department Overview

Pre·ci·sion
Rheu·ma·tol·o·gy

/ ˈpreSHən ˌro͞oməˈtäləjē / · noun

noun · molecular immunology

The integration of genomic, immunophenotypic, and multi-omic profiling with advanced autoimmune diagnostics moving beyond symptom-based disease classification to the molecular and immunological root causes driving inflammation, joint destruction, and systemic autoimmunity in each individual patient.

Origin

From Latin praecisio (exactness) + Greek rheuma (flowing discharge) + -logia (study of). The precision rheumatology paradigm emerged as whole-exome sequencing, single-cell immunoprofiling, and cytokine network analysis revealed that clinically indistinguishable autoimmune phenotypes such as seronegative RA or undifferentiated connective tissue disease harbor molecularly distinct endotypes requiring fundamentally different therapeutic strategies.

The Precision Rheumatology Department at the American Board of Precision Medicine trains clinicians to look beyond clinical criteria and serology integrating HLA haplotyping, autoantibody arrays, T-cell and B-cell immunophenotyping, cytokine profiling, and synovial tissue transcriptomics into a molecularly complete picture of each patient's autoimmune architecture and disease trajectory.

From JAK-STAT pathway dysregulation and type I interferon signatures to complement system activation, NETosis-driven tissue damage, and the gut microbiome's role in autoimmune flare, this department equips physicians with the molecular fluency to match each patient's immunological endotype to the targeted biologic or small-molecule therapy most likely to achieve and sustain remission.

Autoimmune disease is not a single diagnosis — it is a spectrum of molecularly distinct immune dysregulations converging on shared clinical phenotypes. At ABOPM, Precision Rheumatology provides the immunological and genomic framework to resolve that complexity for every patient, individually replacing trial-and-error biologic cycling with targeted, endotype-matched intervention from day one.

100+

Autoimmune Diseases

Endo

Type Matched Therapy

Zero

Trial & Error Cycling

Precision Rheumatology Department · ABOPM

Where Immunological Precision Ends
Trial-and-Error Autoimmune Care

The Precision Rheumatology Department at ABOPM is redefining autoimmune care training physicians to look beyond clinical criteria and serology, integrating HLA haplotyping, autoantibody arrays, cytokine network profiling, and single-cell immunophenotyping into a molecularly complete picture of each patient's immune architecture, enabling endotype-matched therapy from day one.

Immunogenomics & Endotyping

Advancing clinical application of HLA haplotyping, autoantibody array profiling, T-cell and B-cell immunophenotyping, and synovial tissue transcriptomics enabling physicians to resolve the molecular heterogeneity beneath shared autoimmune phenotypes and match each patient's immunological endotype to the most effective targeted therapy.

Molecular Pathway & Cytokine Analysis

Bridging immune dysregulation and clinical management developing board-certified frameworks for JAK-STAT pathway assessment, type I interferon signature profiling, complement activation analysis, NETosis-driven tissue damage evaluation, and gut microbiome–autoimmune axis integration to inform biologic and small-molecule selection.

Physician Education

Building the next generation of precision rheumatologists through rigorous board standards, molecular immunology training, and interdisciplinary collaboration across clinical immunology, genomics, translational pharmacology, musculoskeletal medicine, and systems biology.

"No two autoimmune diseases are molecularly the same even when they carry the same diagnosis. The Precision Rheumatology Department at ABOPM trains physicians to resolve that molecular heterogeneity, replacing trial-and-error biologic cycling with endotype-matched intervention that is uniquely calibrated to each patient's immune biology."

American Board of Precision Medicine · Precision Rheumatology Department

Become a Member → Support Our Mission → Get Involved →

Precision Rheumatology Department · ABOPM

Resolving Immune Molecular Heterogeneity
to Deliver Endotype-Matched Autoimmune Care

No two autoimmune diseases are molecularly identical - even when they carry the same clinical label. Behind every seronegative RA, every undifferentiated connective tissue disease, and every treatment-refractory lupus lies a distinct immunological substrate - HLA haplotypes, cytokine network signatures, T-cell and B-cell endotypes, and pathway-specific dysregulations that population-level diagnostic criteria and trial-and-error biologic cycling were never designed to resolve. Matching each patient's immune endotype to the therapy most likely to achieve durable remission, rather than cycling through biologics empirically, is not a luxury - it is the immunological obligation of modern precision rheumatology.

Precision rheumatology equips clinicians to move beyond clinical criteria and serology and into molecularly stratified autoimmune care - applying HLA haplotyping, autoantibody array profiling, single-cell immunophenotyping, and cytokine network analysis to identify each patient's specific immune architecture and deploy targeted therapy from the first treatment decision.

By mastering precision rheumatology, clinicians gain the power to:

01

Resolve Each Patient's Immunological Endotype

Move beyond ACR/EULAR criteria and serology to stratify each patient's autoimmune disease by its molecular endotype - applying HLA haplotyping, autoantibody array profiling, and single-cell T-cell and B-cell immunophenotyping to identify the specific immune dysregulation architecture driving their disease and distinguish it from superficially similar phenotypes that require fundamentally different treatment strategies.

02

Profile Cytokine Networks and Pathway Dysregulation

Apply JAK-STAT pathway assessment, type I interferon signature profiling, IL-6 and TNF network analysis, and complement activation mapping to identify which inflammatory circuits are dominant in each patient's disease enabling mechanistically matched biologic selection that targets the specific immune pathway driving tissue damage rather than empirically cycling through available agents.

03

Integrate Synovial and Tissue Transcriptomics

Apply synovial tissue transcriptomic profiling, single-cell RNA sequencing of immune infiltrates, and tissue-resident immune cell analysis to characterize the molecular environment at the site of disease revealing endotype-specific cellular compositions and gene expression signatures that predict biologic response and guide targeted therapy selection with precision no serum biomarker alone can achieve.

04

Apply Microbiome and Environmental Axis Analysis

Integrate gut microbiome dysbiosis profiling, NETosis-driven tissue damage assessment, and environmental exposure mapping to identify the modifiable upstream drivers of immune dysregulation enabling precision interventions that address root-cause triggers of autoimmune flare and progression rather than suppressing their downstream inflammatory outputs alone.

05

Lead Precision Rheumatology at Your Institution

Become the molecular immunology and precision rheumatology authority your institution needs - the rheumatologist who leads endotype-matched biologic programs, molecular autoimmune disease clinics, and institutional initiatives that replace empirical treatment cycling with individualized, immune-architecture-guided therapeutic strategies that achieve durable remission from day one.

Why Precision Rheumatology Certification Is Non-Negotiable

Every autoimmune disease has a molecular identity. The question is, are you equipped to read it?

Endotype-Driven Outcomes

Immunologically matched therapy consistently outperforms empirical biologic cycling delivering measurably better remission rates, fewer treatment failures, and reduced cumulative disease damage by targeting the specific molecular immune mechanisms driving each patient's autoimmune disease from the first treatment decision rather than the third or fourth.

Future-Ready Practice

Single-cell immunophenotyping, synovial transcriptomics, multi-target small molecules, and AI-driven endotype classification are transforming rheumatology - physicians board-certified in precision rheumatology will define the next generation of molecularly stratified, endotype-guided autoimmune care.

Clinical Authority

Board certification in precision rheumatology marks you as the molecular immunology and autoimmune endotyping authority - a physician equipped to lead complex autoimmune disease programs, molecular rheumatology clinics, and institutional biologic stewardship initiatives grounded in immunological precision rather than empirical trial and error.

Cross-Subspecialty Impact

Precision rheumatology principles apply across RA, SLE, inflammatory myopathies, vasculitis, spondyloarthropathies, and undifferentiated CTD giving you a universal immunological framework to resolve molecular heterogeneity and deploy endotype-matched therapy across the full spectrum of autoimmune and inflammatory disease.

Active research areas driving precision rheumatology forward:

01

Autoimmune Endotype Stratification

Advancing the molecular classification of autoimmune diseases beyond ACR/EULAR criteria — applying HLA haplotyping, autoantibody array profiling, single-cell T-cell and B-cell immunophenotyping, and synovial tissue transcriptomics to define biologically coherent endotypes within RA, SLE, myositis, and vasculitis that predict biologic response, disease trajectory, and comorbidity risk with a precision no serology panel alone can achieve.

02

Cytokine Network & Signaling Pathway Profiling

Mapping the cytokine network architectures and signaling pathway signatures that distinguish immunological endotypes within shared autoimmune phenotypes — developing JAK-STAT, type I interferon, IL-17, IL-6, and TNF pathway activity scoring methods that identify the dominant immune circuits driving tissue damage in each patient and predict which targeted biologic or small-molecule intervention will most effectively achieve and sustain remission.

03

Synovial Tissue Transcriptomics & Single-Cell Immunology

Applying single-cell RNA sequencing, spatial transcriptomics, and mass cytometry to characterize the immune cellular landscape at the site of autoimmune tissue destruction — defining synovial lining cell subtypes, tissue-resident memory T-cell populations, and pathogenic B-cell clusters whose abundance and gene expression signatures predict biologic treatment response and guide precision therapy selection at the tissue level.

04

NETosis, Complement & Innate Immune Pathway Research

Advancing the clinical characterization of NETosis-driven tissue damage, complement pathway activation scoring, and innate immune circuit dysregulation in SLE, ANCA vasculitis, and antiphospholipid syndrome — developing validated biomarker panels for neutrophil extracellular trap burden, complement consumption, and type I interferon score that translate complex innate immune biology into actionable therapeutic targets and treatment monitoring tools.

05

Microbiome-Autoimmune Axis & Environmental Triggers

Characterizing the gut and oral microbiome dysbiosis patterns, microbial antigen molecular mimicry mechanisms, and environmental exposure signatures that trigger and perpetuate autoimmune disease — building the evidence base for microbiome-targeted interventions, dietary immune modulation protocols, and environmental exposure mitigation strategies that address the upstream modifiable drivers of autoimmune flare and progression in individual patients.

Precision Rheumatology Research · ABOPM

Resolving the Molecular Heterogeneity of Autoimmune Disease

The precision rheumatology revolution is not a future event — it is rewriting how autoimmune disease is classified and treated today. Autoimmune endotype stratification, cytokine network profiling, synovial single-cell transcriptomics, NETosis biomarker development, and microbiome-immune axis research are actively transforming how every inflammatory and autoimmune condition is diagnosed, stratified, and therapeutically targeted at the molecular and individual patient level.

The ABOPM Precision Rheumatology Department positions clinicians at the center of this transformation — equipping them with the molecular immunology literacy, endotype classification frameworks, and board-certified credentials to lead precision autoimmune care across every rheumatological disease and patient presentation.

100+

Distinct autoimmune diseases with molecular endotype heterogeneity

50%

Of RA patients fail their first biologic under empirical selection

Endo

Type-matched therapy replacing trial-and-error biologic cycling

Explore Blog Topics → Read clinical insights, case studies & precision rheumatology updates on our blog

Precision Rheumatology Department · ABOPM

Meet Our Leadership

Director of Precision Rheumatology

Director

Precision Rheumatology

Director of Precision Rheumatology Co-Founder · Precision Longevity Inc.

Saeed Shaikh, MD, F.R.C.P.C.

Rheumatologist · Precision Longevity · Georgetown · McMaster University · Asst. Clinical Professor

"Bridging precision rheumatology and healthy aging — applying advanced immunological insight to inflammatory disease management and longevity medicine for individualized, durable patient outcomes."

Dr. Shaikh is the co-founder of Precision Longevity Inc. and Director of the Niagara Peninsula Arthritis Centre. A native of Toronto, he holds a Bachelor of Arts from the University of Toronto and a Doctor of Medicine from the Royal College of Surgeons in Ireland.

He completed his Residency in Internal Medicine at the Medical Center of Delaware and Fellowship in Rheumatology at Georgetown University in Washington, DC, earning board certifications in both Internal Medicine and Rheumatology in the United States and Canada. He has served on the Board of Directors for the Canadian Rheumatology Research Consortium, is currently an Assistant Clinical Professor at McMaster University, serves on the Scientific Advisory Council for Osteoporosis Canada, and is an active member of the Healthy Longevity Medicine Society.

Dual

US & Canadian Board Certified

CRRC

Board of Directors

Longe
vity

Medicine Society Member

Connect on LinkedIn

Faculty Members

Our faculty roster is growing — announcements coming soon.

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Think you're the right fit for a faculty position?

Get Involved →

Genomics Department · ABOPM

Shaping the Future
of Precision Medicine

As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.

The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.

Explore Certification → Get Involved

Featured Insights

Insights Shaping
Precision Medicine

Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.

Multi-Omics Clinical Innovation Precision Prevention Physician Leadership

Liquid Biopsy and Early Cancer Detection: Promise and Limitations

Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring. ...more

Precision Oncology

June 05, 2026•9 min read

Polygenic Risk Scores and the Genomic Data Gap: Promise, Limitations, and Equity in Precision Medicine

Polygenic risk scores may transform disease prediction, but gaps in genomic diversity continue to limit equity, accuracy, and access in precision medicine across global populations. ...more

Population Precision

May 26, 2026•9 min read

Artificial Intelligence in Precision Medicine

Artificial intelligence is reshaping precision medicine by improving diagnostics, predicting treatment response, and enabling more personalized, data-driven healthcare strategies. ...more

On the Frontier

May 20, 2026•9 min read